Why the study?
Does systematic duplex ultrasound screening before discharge reduce costs compared to prolonged LMWH prophylaxis in patients undergoing total hip replacement?
Does systematic duplex ultrasound screening before discharge reduce costs compared to prolonged LMWH prophylaxis in patients undergoing total hip replacement?
Systematic duplex ultrasound screening before discharge may be more cost-effective than prolonging LMWH prophylaxis to 35 days after total hip replacement.
Answers are grounded in this paper and cite their sources.
May favor pre-discharge duplex over extended LMWH for cost per life saved after hip replacement; leaves open prospective randomized validation.
Background: Despite use of the anti-thrombotic prophylaxis, clinical thrombo-embolic events and fatal pulmonary embolism are still observed after total hip replacement. To reduce these complications, two strategies have been adopted: to prolong the use of low-molecular-weight heparins (LMWH) to 35 days or to screen patients systematically before discharge, using duplex ultrasonography, following the short-course prophylactic treatment. Objective: To assess, based on published literature, the relative costs and benefits of these two strategies for prophylaxis following total hip arthroplasty. Method: The author identified relevant papers in this field from his own resources and from medical literature databases. Synthesis: Prolonging LMWH treatment to a total of 35 days represents a direct cost in France of approximately £340 per patient, or for 100000 total hip replacements per year, an annual budget of £34 000000. If this strategy attained maximum efficacy, it would avoid 150 fatal pulmonary embolisms. The direct cost would therefore be at least £227000 per life saved. A systematic single duplex ultrasound examination before discharge from hospital would cost £76 per patient, or for 100 000 arthroplasties a total annual budget in France of £7 600000. If this approach achieved maximum efficacy, preventing the 150 fatal pulmonary embolisms corresponding to 100000 total hip replacements, the minimum direct cost would be £50 300 per life saved. Conclusion: Duplex screening may be more effective and lest costly than prolongation of prophylactic treatment using LMWH. This deduction needs to be confirmed by complex cost-benefit studies using clinical end-points.
No takes yet. Share an insight, caveat, or question.
M.‐T. Barrellier (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: